IL313333A - EGFR-CMET-Targeted Compounds and Their Uses - Google Patents

EGFR-CMET-Targeted Compounds and Their Uses

Info

Publication number
IL313333A
IL313333A IL313333A IL31333324A IL313333A IL 313333 A IL313333 A IL 313333A IL 313333 A IL313333 A IL 313333A IL 31333324 A IL31333324 A IL 31333324A IL 313333 A IL313333 A IL 313333A
Authority
IL
Israel
Prior art keywords
cmet
egfr
targeted compounds
targeted
compounds
Prior art date
Application number
IL313333A
Other languages
English (en)
Hebrew (he)
Inventor
Sadaf Aghevlian
Andrew Grier Buchanan
Frank Irvine Comer
Qun Du
Ian R Duffy
Natalie Grinshtein
Srinath Kasturirangan
Thomas I Kostelnik
Yariv Mazor
Chunning Yang
Original Assignee
Astrazeneca Uk Ltd
Fusion Pharmaceuticals Inc
Sadaf Aghevlian
Andrew Grier Buchanan
Frank Irvine Comer
Qun Du
Ian R Duffy
Natalie Grinshtein
Srinath Kasturirangan
Thomas I Kostelnik
Yariv Mazor
Chunning Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Fusion Pharmaceuticals Inc, Sadaf Aghevlian, Andrew Grier Buchanan, Frank Irvine Comer, Qun Du, Ian R Duffy, Natalie Grinshtein, Srinath Kasturirangan, Thomas I Kostelnik, Yariv Mazor, Chunning Yang filed Critical Astrazeneca Uk Ltd
Publication of IL313333A publication Critical patent/IL313333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL313333A 2021-12-20 2022-12-20 EGFR-CMET-Targeted Compounds and Their Uses IL313333A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291910P 2021-12-20 2021-12-20
PCT/US2022/082021 WO2023122588A2 (en) 2021-12-20 2022-12-20 Egfr-cmet–targeted compounds and uses thereof

Publications (1)

Publication Number Publication Date
IL313333A true IL313333A (en) 2024-08-01

Family

ID=86903719

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313333A IL313333A (en) 2021-12-20 2022-12-20 EGFR-CMET-Targeted Compounds and Their Uses

Country Status (15)

Country Link
US (1) US20250121104A1 (enExample)
EP (1) EP4452954A2 (enExample)
JP (1) JP2025500944A (enExample)
KR (1) KR20240125970A (enExample)
CN (1) CN118765273A (enExample)
AR (1) AR128052A1 (enExample)
AU (1) AU2022419564A1 (enExample)
CA (1) CA3244030A1 (enExample)
CL (1) CL2024001832A1 (enExample)
CO (1) CO2024008733A2 (enExample)
CR (1) CR20240254A (enExample)
IL (1) IL313333A (enExample)
MX (1) MX2024007596A (enExample)
TW (1) TW202333799A (enExample)
WO (1) WO2023122588A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3265502A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DOTA ANTIBODY CONJUGATES VHH
EP4763865A1 (en) * 2023-08-14 2026-06-24 Minghui Pharmaceutical (Hangzhou) Limited Anti-c-met nanobody and use thereof
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
CN118085101A (zh) * 2024-03-01 2024-05-28 烟台蓝纳成生物技术有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用
WO2025195500A1 (zh) * 2024-03-22 2025-09-25 康源博创生物科技(北京)有限公司 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用
WO2026149557A1 (zh) * 2025-01-10 2026-07-16 正大天晴药业集团股份有限公司 新型亲水性连接体及其药物连接体、蛋白质偶联药物、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
WO2021133036A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
KR20220157464A (ko) * 2020-03-23 2022-11-29 퓨전 파마슈티칼즈 인크. Fgfr3-표적화된 방사선면역접합체 및 그의 용도
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof

Also Published As

Publication number Publication date
KR20240125970A (ko) 2024-08-20
CA3244030A1 (en) 2023-06-29
CN118765273A (zh) 2024-10-11
MX2024007596A (es) 2024-07-09
US20250121104A1 (en) 2025-04-17
TW202333799A (zh) 2023-09-01
CL2024001832A1 (es) 2024-11-22
JP2025500944A (ja) 2025-01-15
EP4452954A2 (en) 2024-10-30
AR128052A1 (es) 2024-03-20
AU2022419564A1 (en) 2024-07-04
WO2023122588A3 (en) 2023-09-21
CO2024008733A2 (es) 2024-07-29
CR20240254A (es) 2025-01-13
WO2023122588A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
IL327255A (en) Heterocyclic pyrimido compounds and their uses
CA3244030A1 (en) COMPOUNDS TARGETED BY EGFR-CMET AND THEIR USES
IL285177A (en) compounds and their use
IL304222A (en) Alternative pyridotriazine compounds and their uses
IL286497A (en) compounds and their use
IL316531A (en) Compounds and their uses
CA203180S (en) Fastener
GB202002010D0 (en) Microtopographies and uses thereof
CA199288S (en) Glove
CA203329S (en) Glove
IL291499A (en) Azaquinoline compounds and their uses
IL284764A (en) compounds and their uses
CA211462S (en) Glove
GB202001017D0 (en) Ammonia
IL311521A (en) Compounds targeting EGFRVIII and their uses
CA211463S (en) Glove
CA213072S (en) Glove
ZA202201239B (en) Aminothiolester compounds and uses thereof
CA203328S (en) Glove
GB202112054D0 (en) Trespassing deterrence
GB202019660D0 (en) Uses and methods
GB202105483D0 (en) Compounds and uses thereof
CA211473S (en) Glove
CA211476S (en) Glove
CA211477S (en) Glove